Cronos Group Inc. - Common Share (CRON): Price and Financial Metrics
CRON Price/Volume Stats
Current price | $1.75 | 52-week high | $3.62 |
Prev. close | $1.75 | 52-week low | $1.67 |
Day low | $1.69 | Volume | 1,291,800 |
Day high | $1.77 | Avg. volume | 1,499,527 |
50-day MA | $1.87 | Dividend yield | N/A |
200-day MA | $2.52 | Market Cap | 666.43M |
CRON Stock Price Chart Interactive Chart >
CRON POWR Grades
- CRON scores best on the Growth dimension, with a Growth rank ahead of 58.08% of US stocks.
- The strongest trend for CRON is in Value, which has been heading up over the past 179 days.
- CRON ranks lowest in Momentum; there it ranks in the 0th percentile.
CRON Stock Summary
- The ratio of debt to operating expenses for CRONOS GROUP INC is higher than it is for about merely 4.98% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.04 for CRONOS GROUP INC; that's greater than it is for merely 7.06% of US stocks.
- With a year-over-year growth in debt of -43.12%, CRONOS GROUP INC's debt growth rate surpasses just 6.95% of about US stocks.
- If you're looking for stocks that are quantitatively similar to CRONOS GROUP INC, a group of peers worth examining would be FTHM, OGI, VEEE, AMRN, and LIQT.
- Visit CRON's SEC page to see the company's official filings. To visit the company's web site, go to www.thecronosgroup.com.
CRON Valuation Summary
- CRON's EV/EBIT ratio is -2; this is 116.67% lower than that of the median Healthcare stock.
- CRON's price/sales ratio has moved down 2663.3 over the prior 64 months.
Below are key valuation metrics over time for CRON.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CRON | 2023-05-23 | 8.3 | 0.6 | -4.6 | -2.0 |
CRON | 2023-05-22 | 8.7 | 0.7 | -4.9 | -2.2 |
CRON | 2023-05-19 | 8.4 | 0.6 | -4.7 | -2.0 |
CRON | 2023-05-18 | 8.0 | 0.6 | -4.5 | -1.8 |
CRON | 2023-05-17 | 7.7 | 0.6 | -4.3 | -1.6 |
CRON | 2023-05-16 | 7.5 | 0.6 | -4.2 | -1.6 |
CRON Growth Metrics
- Its 3 year price growth rate is now at -77.43%.
- The 2 year net cashflow from operations growth rate now stands at 8.48%.
- Its 4 year net income to common stockholders growth rate is now at 47579.27%.

The table below shows CRON's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 94.812 | -100.514 | -223.487 |
2022-06-30 | 94.296 | -118.61 | -108.58 |
2022-03-31 | 86.857 | -141.525 | -267.433 |
2021-12-31 | 74.435 | -153.616 | -396.107 |
2021-09-30 | 65.686 | -155.451 | -373.703 |
2021-06-30 | 56.637 | -151.461 | -146.458 |
CRON's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRON has a Quality Grade of F, ranking ahead of 0.86% of graded US stocks.
- CRON's asset turnover comes in at 0.03 -- ranking 353rd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CRON's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.030 | -0.621 | -0.378 |
2021-03-31 | 0.027 | -0.439 | -0.870 |
2020-12-31 | 0.024 | -0.553 | -0.242 |
2020-09-30 | 0.019 | -0.749 | 0.191 |
2020-06-30 | 0.015 | -1.350 | 2.033 |
2020-03-31 | 0.014 | -1.185 | 6.271 |
CRON Price Target
For more insight on analysts targets of CRON, see our CRON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $6.63 | Average Broker Recommendation | 2.42 (Moderate Sell) |
Cronos Group Inc. - Common Share (CRON) Company Bio
Cronos Group seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations. The firm typically invests in companies based in Canada. Cronos Group was founded in January, 2013 and is based in Toronto, Canada.
Latest CRON News From Around the Web
Below are the latest news stories about CRONOS GROUP INC that investors may wish to consider to help them evaluate CRON as an investment opportunity.
The Canadian Cannabis Report - Monday, May 15The past, present and future of the Canadian cannabis sector based on the performance of the MCCCI, which is a proprietary index of 16 sector stocks. |
Cronos Group Inc. to Speak at the Canaccord Genuity 7th Annual Global Cannabis ConferenceTORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the Canaccord Genuity 7th Annual Global Cannabis Conference on Thursday, May 18, 2023, at 11:00AM ET. A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group In |
Cannabis LPs Remain Volatile: +10% Last Week; -10% So Far This WeekA look at the five largest licensed producers (LPs), as tracked in our Canadian Cannabis LPs Index |
Top Cannabis Stocks for May 2023Cresco Labs, SNDL, and Green Thumb Industries top peers for best value, fastest growth, and best performance, respectively. |
Cronos Group First Quarter 2023 Earnings: Misses ExpectationsCronos Group ( TSE:CRON ) First Quarter 2023 Results Key Financial Results Revenue: US$20.1m (down 20% from 1Q 2022... |
CRON Price Returns
1-mo | -5.41% |
3-mo | -17.45% |
6-mo | -49.42% |
1-year | -38.81% |
3-year | -73.56% |
5-year | -74.42% |
YTD | -31.10% |
2022 | -35.20% |
2021 | -43.52% |
2020 | -9.52% |
2019 | -26.18% |
2018 | 34.43% |
Continue Researching CRON
Here are a few links from around the web to help you further your research on Cronos Group Inc's stock as an investment opportunity:Cronos Group Inc (CRON) Stock Price | Nasdaq
Cronos Group Inc (CRON) Stock Quote, History and News - Yahoo Finance
Cronos Group Inc (CRON) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...